Zilucoplan Side Effects
Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.
Applies to zilucoplan: parenteral injection for sub-q use.
Important warnings
This medicine can cause some serious health issues
REMS:
FDA approved a REMS for zilucoplan to ensure that the benefits outweigh the risks.
The REMS may apply to one or more preparations of zilucoplan and consists of the following: elements to assure safe use and implementation system.
See the FDA REMS page ([Web]) for specific information.
Side effects include:
Most common adverse effects (≥10%): injection site reactions, upper respiratory tract infection, diarrhea.
See also:
Rystiggo
Rystiggo is used to treat generalized myasthenia gravis (gMG) in adults who are acetylcholine ...
Mestinon
Mestinon (pyridostigmine) is used to increase muscle strength in conditions such as myasthenia ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Vyvgart
Vyvgart is used for myasthenia gravis to improve muscle weakness in adults whose myasthenia gravis ...
Vyvgart Hytrulo
Vyvgart Hytrulo is used to treat generalized myasthenia gravis (gMG) or chronic inflammatory ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Imaavy
Imaavy (nipocalimab-aahu) is a new medication used to treat generalized myasthenia gravis (gMG) ...
Eculizumab
Eculizumab (brand names Soliris, Bkemv, and Epysqli) is used to treat paroxysmal nocturnal ...
Neostigmine
Neostigmine is used for myasthenia gravis, reversal of neuromuscular blockade, reversal of ...
For healthcare professionals
Applies to zilucoplan: subcutaneous solution.
General adverse events
The most common adverse effects in at least 10% of patients were injection site reactions, upper respiratory tract infections, and diarrhea.[Ref]
Dermatologic
- Postmarketing reports: Morphea[Ref]
Gastrointestinal
- Very common (10% or more): Diarrhea (up to 11%)
- Common (1% to 10%): Nausea, vomiting, increased lipase, increased amylase
- Frequency not reported: Pancreatic events (included pancreatitis and pancreatic cysts)[Ref]
Genitourinary
- Common (1% to 10%): Urinary tract infection[Ref]
Hematologic
- Uncommon (0.1% to 1%): Increased blood eosinophils[Ref]
Local
- Very common (10% or more): Injection site reactions (up to 29%), injection site bruising (up to 13.9%)
- Common (1% to 10%): Injection site pain[Ref]
Injection site reactions included injection site bruising, hematoma, pain, reaction, hemorrhage, nodule, pruritus, and rash.[Ref]
Other
- Common (1% to 10%): Contusion
- Frequency not reported: Meningococcal infection[Ref]
Respiratory
- Very common (10% or more): Upper respiratory tract infections (14%)
- Common (1% to 10%): Nasopharyngitis, sinusitis[Ref]
Upper respiratory tract infections included nasopharyngitis, sinusitis, upper respiratory tract infection, and tonsillitis.[Ref]
References
1. (2023) "Product Information. Zilbrysq (zilucoplan)." UCB Pharma Inc
2. (2024) "Product Information. Zilbrysq (zilucoplan)." UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
3. (2024) "Product Information. Zilbrysq (zilucoplan)." UCB Pharma Ltd
4. (2025) "Product Information. Zilbrysq (zilucoplan)." UCB Pharma Inc
Frequently asked questions
More about zilucoplan
- Check interactions
- Compare alternatives
- Reviews (2)
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Zilucoplan side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.
